You are here

Promising Results for Two Beta-Thalassemia Drugs

Ken Attie, MD, Vice President of Medical Research at Acceleron Pharma in Cambridge, Massachusetts, talks about the beta-thalassemia medications his company is developing with Celgene. At a meeting of the European Hematology Association, data from two clinical trials—one for each drug, ACE-011 (sotatercept) and ACE-536—showed varying improvements in red blood cell counts, reductions in transfusions, and relief of fatigue. Both medications have received the FDA’s orphan drug designation.

European Hematology Association, June 2014